| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Mulberrofuran Q targets the cyclooxygenase (COX) pathway, inhibiting the formation of 12-hydroxy-5,8,10-heptadecatrienoic acid (HHT) and thromboxane B2, which are products of cyclooxygenase activity. It also protects neuronal cells from hypoxia-glucose deprivation (OGD)-induced oxidative stress. It inhibits the production of pro-inflammatory cytokines and demonstrates antimicrobial properties against pathogens such as Staphylococcus aureus and Streptococcus mutans.
|
|---|---|
| ln Vitro |
In vitro, Mulberrofuran Q inhibits the formation of HHT and thromboxane B2, which are cyclooxygenase products. It protects neuronal cells from hypoxia-glucose deprivation (OGD)-induced oxidative stress. It exhibits significant anti-inflammatory properties and inhibits the production of pro-inflammatory cytokines. It demonstrates antimicrobial properties against Staphylococcus aureus and Streptococcus mutans.
|
| ln Vivo |
In vivo activity data for Mulberrofuran Q are limited. The compound has been evaluated for its ability to treat neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease. It inhibits the activity of cannabinoid receptors. Specific animal model studies have been reported.
|
| Enzyme Assay |
Specific protocols for enzyme or receptor binding assays have not been established for Mulberrofuran Q. Cyclooxygenase inhibition can be assessed using enzyme activity assays that measure the conversion of arachidonic acid to prostaglandins. Cannabinoid receptor binding can be evaluated using radioligand binding assays.
|
| Cell Assay |
Cell-based assays for Mulberrofuran Q include evaluating its neuroprotective effects in neuronal cells exposed to oxygen-glucose deprivation (OGD). Anti-inflammatory effects can be assessed in macrophage cell lines by measuring cytokine production. Antimicrobial activity is evaluated using standard MIC assays against bacterial pathogens.
|
| Animal Protocol |
In vivo animal protocols for Mulberrofuran Q involve evaluating its ability to treat neurodegenerative diseases in animal models. Specific protocols for Parkinson's disease and Alzheimer's disease models have been reported. The compound's effects on cannabinoid receptor activity have also been evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Mulberrofuran Q are not extensively reported. The compound has a molecular weight of 592.5 and a molecular formula of C34H24O10. It is stored under standard conditions for natural products. As a flavonoid, it is likely to have moderate oral bioavailability.
|
| Toxicity/Toxicokinetics |
Toxicological data for Mulberrofuran Q are limited. The compound exhibits neuroprotective and anti-inflammatory activities. As a research-use-only compound, it has not undergone formal safety assessment. Standard laboratory precautions should be observed.
|
| References |
[1]. Kimura Y, Okuda H, Nomura T, Fukai T, Arichi S. Effects of phenolic constituents from the mulberry tree on arachidonate metabolism in rat platelets. J Nat Prod. 1986;49(4):639-644.
|
| Additional Infomation |
Samfuran Q is a benzofuran compound. It has been reported that sanfuran Q has been detected in Mongolian mulberry (Morus mongolica), and relevant data are available for reference.
Mulberrofuran Q is a research-use-only compound. It is an active compound found in mulberry (Morus species) root and bark. It inhibits the formation of HHT and thromboxane B2 (cyclooxygenase products) and protects neuronal cells from OGD-induced oxidative stress. It exhibits anti-inflammatory, antimicrobial, neuroprotective, and potential anticancer activities. It is used in natural product and neurodegenerative disease research. |
| Molecular Formula |
C34H24O10
|
|---|---|
| Molecular Weight |
592.54836
|
| Exact Mass |
592.137
|
| CAS # |
101383-35-1
|
| PubChem CID |
5319933
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.633
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
44
|
| Complexity |
1180
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1=CC=C(C23OC4=CC(C5OC6=CC(=CC=C6C=5)O)=CC(O)=C4C4C(C5(OC6=CC(=CC=C6[C@@H](C24O3)C5)O)C)=O)C(O)=C1
|
| InChi Key |
MSVXRBNAPJJEDX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C34H24O10/c1-32-14-22(20-6-4-19(37)13-27(20)42-32)33-30(31(32)40)29-24(39)8-16(25-9-15-2-3-18(36)12-26(15)41-25)10-28(29)43-34(33,44-33)21-7-5-17(35)11-23(21)38/h2-13,22,30,35-39H,14H2,1H3
|
| Chemical Name |
4-(2,4-dihydroxyphenyl)-10,18-dihydroxy-8-(6-hydroxy-1-benzofuran-2-yl)-14-methyl-3,5,15-trioxahexacyclo[12.7.1.02,4.02,12.06,11.016,21]docosa-6,8,10,16(21),17,19-hexaen-13-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6876 mL | 8.4381 mL | 16.8762 mL | |
| 5 mM | 0.3375 mL | 1.6876 mL | 3.3752 mL | |
| 10 mM | 0.1688 mL | 0.8438 mL | 1.6876 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
